The purinergic 2 × 7 (P2 × 7) receptor antagonist, which is an inhibitor of the P2 × 7/NLRP3/caspase-1 pathway in microglia, might exert an anti-neuroinflammatory effect and be applicable for treating early-stage AD (Thawkar and Kaur, 2019). The gene discussed is NLRP3; the disease is Alzheimer disease.